Abstract Background Clear cell renal cell carcinoma (ccRCC) is defined by constitutive pseudohypoxia driven by von Hippel-Lindau (VHL) loss, pronounced intratumoral heterogeneity, and aberrant hypervascularity, features that collectively promote tumor progression and limit therapeutic durability. Although VEGF-targeted...
B. Ulukan, O. Saatci, A. Madrigal et al.· The Oncologist· 0 citations
The “one-two punch” approach combining LOX inhibition with clinical DHODH inhibitor suppresses tumor growth in vivo in chemo-free setting and shows that inhibiting LOX generates targetable vulnerability to ferroptosis.
O. Saatci, B. Ulukan, Metin Cetin et al.· Cell Reports Medicine· 1 citation
Using single-cell transcriptomics, lysyl oxidase (LOX) is identified as a driver of ccRCC progression, selectively enriched in a hypoxia/epithelial-mesenchymal transition (EMT) gene program associated with poor outcome.
B. Ulukan, O. Saatci, A. Madrigal et al.· bioRxiv· 0 citations
These studies establish selective inhibition of the PLK1 Polo-box domain as a viable therapeutic strategy, provide in vivo proof-of-concept for the REPLACE approach, and identify abbapolins as promising leads for advanced prostate cancer.
George Merhej, Gurusankar Ramamoorthy, Danda Chapagai et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
